US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stage

0.3754

+0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

Loading ...

Overview Company News Filings

Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial

MT Newswires Live

Worried About How President Donald Trump's Social Security Plans Could Affect Your Retirement? Do These 4 Things to Prepare Now.

Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results

Ballymore Resources to Commence Stage 5 Drilling at Dittmer Gold Project

HIVE Digital Technologies Announces the Acquisition of Bitfarms' Yguazú, Paraguay Site, a 200 MW Bitcoin Mining Site, Setting the Stage for Substantial Growth to 25 EH/s by September 2025

Smead Value Fund's Strategic Moves: Ulta Beauty Inc. Takes Center Stage

MSFT Q2 Earnings Preview: Azure Cloud Innovation Takes Center Stage

Introducing the New Harley-Davidson® Audio Powered by Rockford Fosgate® Stage III Audio Systems

Garden Stage Limited Reports First Half 2025 Financial Results

Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

FX Guys Surges in Stage 2 With Over $3M Raised—Can It Leave Injective and Near Protocol Behind?

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Robert Olstein's Strategic Moves: Nike Inc. Takes Center Stage in Q4 2024 Portfolio

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"04-09 16:46:54 EDT","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1744243200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507540639","title":"Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2507540639","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507540639?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:18","pubTimestamp":1738160331,"startTime":"0","endTime":"0","summary":"Greenwich LifeSciences  said Wednesday that the European Medicines Agency has approved its application to add 11 new sites in Spain, Germany, and Poland for a late-stage trial of GLSI-100 to prevent breast cancer recurrences.The company said that with the latest approval, regulators have cleared the way for the activation of  110 to 115 sites in Europe.Greenwich said it plans to file applications with the EMA to add 5 to 10 additional sites in Ireland, Romania, and potentially other European countries.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLSI","BK4156","BK4139","SSI"],"gpt_icon":0},{"id":"2507839466","title":"Worried About How President Donald Trump's Social Security Plans Could Affect Your Retirement? Do These 4 Things to Prepare Now.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507839466","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507839466?lang=en_us&edition=fundamental","pubTime":"2025-01-29 16:15","pubTimestamp":1738138500,"startTime":"0","endTime":"0","summary":"Social Security is facing an uncertain future due to dwindling trust funds and President Trump's promise to eliminate benefit taxes.Saving as much as you can for retirement is the best way to increase your future financial security.Those already in retirement can benefit from finding part-time employment or applying for other government benefits.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/retirement/2025/01/29/worried-about-how-president-donald-trumps-social-s/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4554","FRA","BK4576","BK4508","SSI","BK4077","BK4551"],"gpt_icon":0},{"id":"2506246515","title":"Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2506246515","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506246515?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:25","pubTimestamp":1738070700,"startTime":"0","endTime":"0","summary":"Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.The Cambridge, Mass., biotech firm said colorectal cancer patients participating in the DeFianCe phase 2 clinical trial treated with its sirexatamab product candidate plus bevacizumab, a drug sold under the brand Avastin, and chemotherapy had an objective response rate of 35% and disease control rate of 86%. That was a slight improvement on the objective response rate of 23% and disease-control of 84% in a control group treated with bevacizumab and chemotherapy alone.\"These data support moving forward into phase 3 registrational studies to further explore a unique treatment option for patients in need,\" said Zev Wainberg, professor of medicine and co-director of the GI Oncology Program at UCLA.Patients with gastroesophageal junction and gastric cancer participating in the DisTinGuish mid-stage phase 2 tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","SSI","LENZ","BK4505","BK4139","LPTX"],"gpt_icon":0},{"id":"2506569488","title":"Ballymore Resources to Commence Stage 5 Drilling at Dittmer Gold Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2506569488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506569488?lang=en_us&edition=fundamental","pubTime":"2025-01-28 14:57","pubTimestamp":1738047431,"startTime":"0","endTime":"0","summary":"Ballymore Resources Limited ( ($AU:BMR) ) has shared an announcement. Ballymore Resources announced its upcoming Stage 5 drilling campaign at the D...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ballymore-resources-to-commence-stage-5-drilling-at-dittmer-gold-project-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ballymore-resources-to-commence-stage-5-drilling-at-dittmer-gold-project-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2506565734","title":"HIVE Digital Technologies Announces the Acquisition of Bitfarms' Yguazú, Paraguay Site, a 200 MW Bitcoin Mining Site, Setting the Stage for Substantial Growth to 25 EH/s by September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2506565734","media":"Newsfile","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506565734?lang=en_us&edition=fundamental","pubTime":"2025-01-28 14:00","pubTimestamp":1738044000,"startTime":"0","endTime":"0","summary":"This news release constitutes a \"designated news release\" for the purposes of the Company's prospectus supplement dated October 3, 2024 to its short form base shelf prospectus dated September 11, 2024.San Antonio, Texas-- - HIVE Digital Technologies Ltd.    , a global leader in sustainable data center infrastructure, is excited to announce the signing of a binding letter of intent  with Bitfarms Ltd. to acquire the Yguazú 200 megawatt  hydro-powered Bitcoin mining facility in Paraguay. This acquisition will accelerate HIVE's growth, increasing its global Bitcoin mining hashrate from 6 Exahash per second  today, to an anticipated 25 EH/s by September 2025, cementing its position as an industry leader .HIVE's enhanced operational capacity in Paraguay will total 300 MW upon completion of this acquisition, bringing its global capacity, including existing facilities in Canada and Sweden, to 430 MW by Q3 2025. This milestone reflects HIVE's commitment to operating entirely on 100% green hydr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hive-digital-technologies-announces-acquisition-060000189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hive-digital-technologies-announces-acquisition-060000189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4601","SSI","HIVE","BK4595","BK4594","BK4585","BK4023","BK4600","BK4588"],"gpt_icon":1},{"id":"2506583359","title":"Smead Value Fund's Strategic Moves: Ulta Beauty Inc. Takes Center Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2506583359","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506583359?lang=en_us&edition=fundamental","pubTime":"2025-01-28 02:00","pubTimestamp":1738000842,"startTime":"0","endTime":"0","summary":"Exploring the Latest Investment Decisions of Smead Value Fund . GuruFocus has detected 7 Warning Signs with SPG.Smead Value Fund  recently submitted its N-PORT filing for the fourth quarter of 2024, shedding light on its strategic investment decisions during this period. Smead Capital Management, the adviser to the Smead Value Fund , caters to a diverse clientele, including individuals, advisors, family offices, and institutions worldwide. The fund primarily invests in U.S. large-cap companies and offers various share classes, such as SMVLX, SVFAX, SVFCX, SVFFX, SVFDX, SVFKX, and SVFYX. Managed by Lead Portfolio Manager Bill Smead and Co-Portfolio Manager Cole Smead, CFA, the fund aims for long-term capital appreciation through concentrated positions, typically holding 25-30 companies. Smead's investment philosophy focuses on eight criteria, including economic need, competitive advantage, profitability, free cash flow, intrinsic value, shareholder-friendly management, strong balance sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/smead-value-funds-strategic-moves-180042621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","TGT","IE00BDRTCR15.USD","LU1267930227.SGD","BK4080","LU1244550577.SGD","APA",".IXIC","IE00BFSS8Q28.SGD","LU2237443895.HKD","MNQmain","LU0215105999.USD","USAW.SI","IE00BKVL7J92.USD","SIRI","LU0267386448.USD","LU0234572021.USD","LU0314104364.USD","LU1366192091.USD","QLD","IE00BYXW3230.USD","LU0942090050.USD","LU2357305700.SGD","NVIW.SI","IE00BSNM7G36.USD","TSYW.SI","LU1119994496.HKD","SSI","LU2237443549.SGD","LU1720051017.SGD","QID","IE00BBT3K403.USD","NQmain","BK4581","LU1670627923.USD","LU1032466523.USD","TQQQ","BK4213","LU2361044865.SGD","SPG","USJW.SI","PSQ","MAC","ULTA","DHI","LEN","LU1914381329.SGD","AXP","BK4559"],"gpt_icon":1},{"id":"2506062193","title":"MSFT Q2 Earnings Preview: Azure Cloud Innovation Takes Center Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2506062193","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506062193?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:56","pubTimestamp":1737986160,"startTime":"0","endTime":"0","summary":"Microsoft’s MSFT second-quarter fiscal 2025 results, scheduled to be reported on Jan. 29, are likely to be driven by steady growth in its cloud platform, Azure. (Read Now: Microsoft Stock Before Q2 Earnings: A Smart Buy or Risky Investment?)For the fiscal second quarter, Microsoft expects Intelligent Cloud revenues  between $25.55 billion and $25.85 billion.Our model estimate for this segment is pegged at $25.69 billion, indicating growth of 19.4% from the figure reported in the year-ago quarter.Azure's Cloud Magic to Spark Microsoft's Q2 Growth. GE Aerospace, for example, used Azure OpenAI to build a new digital assistant for all 52,000 of its employees. In just three months, it has been used to conduct over 500,000 internal queries and process more than 200,000 documents.In the fiscal first quarter, Microsoft added support for OpenAI’s newest model family o1. MSFT is also bringing industry-specific models to Azure AI, including a collection of best-in-class multimodal models for medi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/msft-q2-earnings-preview-azure-135600945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSFT","SSI"],"gpt_icon":1},{"id":"2506894672","title":"Introducing the New Harley-Davidson® Audio Powered by Rockford Fosgate® Stage III Audio Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2506894672","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506894672?lang=en_us&edition=fundamental","pubTime":"2025-01-25 03:00","pubTimestamp":1737745200,"startTime":"0","endTime":"0","summary":"New this year are the 6.5-inch fairing speakers and 6x9 saddlebag speakers, both designed with a 3-way bridge-mounted system to deliver next level performance. The 6.5-inch fairing and 6x9 saddlebag speakers offer an impressive 250 watts per speaker. Additionally, we've introduced notable design updates, including Hot Rod Red trim rings and matching red badging on the grilles.To achieve class-leading sound clarity, every speaker is precisely engineered to align with rider positioning, ensuring music cuts through wind, road, and exhaust noise. Built to withstand the elements, these speakers are Element Ready, performing flawlessly in any weather conditions, including exposure to water, dust, and dirt.Harley-Davidson will offer Stage III in complete audio kits. comprised of 6.5-inch fairing speakers, the 6x9 saddlebag speakers, the 500-watt primary amplifier and the saddlebag installation kit, all in a single box.These all-new Stage III systems will be available through Harley-Davidson d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/introducing-harley-davidson-audio-powered-190000089.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/introducing-harley-davidson-audio-powered-190000089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["III","SSI","BK4091","BK4124","HOG","PATK","BK4134"],"gpt_icon":0},{"id":"2506846898","title":"Garden Stage Limited Reports First Half 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2506846898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506846898?lang=en_us&edition=fundamental","pubTime":"2025-01-25 00:27","pubTimestamp":1737736052,"startTime":"0","endTime":"0","summary":"Garden Stage Ltd. ( ($GSIW) ) has provided an announcement. Garden Stage Limited has announced its unaudited financial results for the first half o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/garden-stage-limited-reports-first-half-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/garden-stage-limited-reports-first-half-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","SSI","GSIW","WIN"],"gpt_icon":0},{"id":"2505629258","title":"Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2505629258","media":"Investopedia","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505629258?lang=en_us&edition=fundamental","pubTime":"2025-01-24 22:41","pubTimestamp":1737729669,"startTime":"0","endTime":"0","summary":"Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.The maker of Ozempic and Wegovy said that its Phase 1b/2a trial showed people achieved weight loss from a mean baseline body weight of 92.7 kg  in three different maintenance doses, while those treated with placebo gained weight.Novo Nordisk shares have been trending lower since September on slowing sales and increasing competition in the weight-loss drug market.Novo Nordisk's  U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.The maker of Ozempic and Wegovy said that its Phase 1b/2aclinical trial showed people achieved weight loss from a mean baseline body weight of 92.7 kg  in three different maintenance doses, while those treated with placebo gained weight. In the highest dosage, 20mg, participants lost 22% of body weight after 36 weeks, whil","market":"hk","thumbnail":"https://www.investopedia.com/thmb/FJTPFL2uR0SaFpZiHrxF5DFzMNw=/5615x3743/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2186511013-35d19a76166947a8a692d8009b279682.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/FJTPFL2uR0SaFpZiHrxF5DFzMNw=/5615x3743/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2186511013-35d19a76166947a8a692d8009b279682.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/novo-nordisk-stock-jumps-on-early-stage-weight-loss-drug-trial-results-8779639","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["SG9999014906.USD","IE00BK4W5L77.USD","BK4516","LU1023059063.AUD","LU1093756168.USD","LU2237443465.HKD","LU2602419157.SGD","BK4585","LU1983299246.USD","LU1868836591.USD","LU1623119135.USD","LU1548497426.USD","LU2106854487.HKD","LU0708995401.HKD","SSI","LU2237443382.USD","LU1093756325.SGD","LLY","BK4532","LU2491049909.HKD","LU2361045086.USD","LU0820561909.HKD","SG9999001176.USD","GB00BDT5M118.USD","IE0009355771.USD","LU1069344957.HKD","LU0689472784.USD","BK4007","LU0238689110.USD","NVO","LU0079474960.USD","LU1127390331.HKD","LU0640476718.USD","LU2264538146.SGD","LU0114720955.EUR","LU2237438978.USD","LU0061475181.USD","NVO.AU","SG9999018865.SGD","LU0203202063.USD","LU2237443895.HKD","LU2237443622.USD","LU2468319806.SGD","LU1720051017.SGD","LU0820561818.USD","LU2237443549.SGD","LU0823416689.USD","LU1868837136.USD","LU0198837287.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2505045131","title":"Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2505045131","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505045131?lang=en_us&edition=fundamental","pubTime":"2025-01-24 00:33","pubTimestamp":1737649998,"startTime":"0","endTime":"0","summary":"On Thursday, Vigil Neuroscience Inc.  released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease.Key takeaways from the Phase 1 clinical trial ofVG-3927 include:. Demonstrated a favorable safety and tolerability profile across all cohorts, including the elderly cohort.All related adverse events were mild or moderate in severity and self-resolving without drug discontinuations. No serious AEs were reported.Highly brain penetrant with a favorable and predictable PK profile that supports once-daily dosing.Achieved robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid , demonstrating a strong PK/PD relationship, sustained target engagement, and TREM2 agonist activity.PK and sTREM2 reduction observed in the Alzheimer’s cohort was consistent with healthy volunteers and similar across evaluated TREM2 and ApoE genetic variants supporting development in Alzheimer’s disease across genotypes.An","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neurosciences-alzheimers-candidate-shows-163318630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","LU2357305700.SGD","BK4581","LU0314104364.USD","LU0225283273.USD","LU2023251221.USD","LU1162221912.USD","LU2347655156.SGD","LU0106261372.USD","LU0795875086.SGD","LU0006306889.USD","LU0106831901.USD","LU0267386448.USD","BK4585","CSF","BK4588","LU1732799900.SGD","LU0912757837.SGD","LU1363072403.SGD","LU1720051108.HKD","LU1548497426.USD","LU2089284900.SGD","LU2133065610.SGD","BK4139","LU1989772840.SGD","VIGL","BK4534","LU0158827781.USD","LU1720051017.SGD","LU1989772923.USD","LU1668664300.SGD","SSI","BK4504","LU1732800096.USD","LU0320765646.SGD","LU0098860793.USD","LU0158827948.USD","BK4127","LU2028103732.USD","LU1074936037.SGD","LU0795875169.SGD","LU2271345857.HKD","LU0971096721.USD","LU2089283258.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU2111349929.HKD"],"gpt_icon":0},{"id":"2505895036","title":"FX Guys Surges in Stage 2 With Over $3M Raised—Can It Leave Injective and Near Protocol Behind?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505895036","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505895036?lang=en_us&edition=fundamental","pubTime":"2025-01-23 10:51","pubTimestamp":1737600685,"startTime":"0","endTime":"0","summary":"The $FXG presale is in Stage 2 of its ICO, with each $FXG token valued at $0.04. This public presale has raised over $3.5 million, selling more than 93% of the allocated tokens for this stage. Due to the high demand for the presale, experts believe that this new cryptocurrency ICO could outpace top players like Injective and Near Protocol once it launches officially.FXGuys’ blockchain trading platform redefines proprietary trading with its unique technology. This project offers features like Trade2Earn, a Trader Funding Program, and staking rewards. These features set the FX Guys project ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6791aeadbf25a83ccec60e2b/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4585","SSI","NEAR","BK4588","BK4533","LU0683600562.USD","BK4512","LU1093756325.SGD","LU1093756168.USD","LU0787776722.HKD","BK4534","MMM","BK4206"],"gpt_icon":0},{"id":"2505074201","title":"bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2505074201","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505074201?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, January 22, 2025----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian Patent Office , has accepted bioAffinity’s patent application for the method of predicting the likelihood of lung cancer used by the CyPath Lung diagnostic test for early-stage lung cancer.bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-announces-acceptance-patent-130000678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","BIAF","BIAFW"],"gpt_icon":0},{"id":"2505751733","title":"Robert Olstein's Strategic Moves: Nike Inc. Takes Center Stage in Q4 2024 Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2505751733","media":"GuruFocus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505751733?lang=en_us&edition=fundamental","pubTime":"2025-01-22 04:40","pubTimestamp":1737492015,"startTime":"0","endTime":"0","summary":"Insightful Analysis of Robert Olstein (Trades, Portfolio)'s Latest 13F Filing Robert Olstein (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2024, providing insights in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2662733/robert-olsteins-strategic-moves-nike-inc-takes-center-stage-in-q4-2024-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["NKE","SSI"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:false,,,undefined,":{}}}